EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Clinical Practice Guideline: Immunotherapy for Inhalant Allergy

Richard K Gurgel, Fuad M Baroody, Cecelia C Damask, James Whit Mims, Stacey L Ishman, Dole P Baker, Kevin J Contrera, Fariha S Farid, John A Fornadley, Donna D Gardner, LaKeisha R Henry, Jean Kim und 7 weitere

Otolaryngology–Head and Neck Surgery · 2024-03 · 170 (S1)

DOI: 10.1002/ohn.648 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Otolaryngology–Head and Neck Surgery, online erschienen am 26.02.2024. Verfasst von Richard K Gurgel und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Anaphylaxis, Asthma, Rhinitis, Allergic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 264 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Allergen immunotherapy (AIT) is the therapeutic exposure to an allergen or allergens selected by clinical assessment and allergy testing to decrease allergic symptoms and induce immunologic tolerance. Inhalant AIT is administered to millions of patients for allergic rhinitis (AR) and allergic asthma (AA) and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). Despite its widespread use, there is variability in the initiation and delivery of safe and effective immunotherapy, and there are opportunities for evidence‐based recommendations for improved patient care.

Purpose

The purpose of this clinical practice guideline (CPG) is to identify quality improvement opportunities and provide clinicians trustworthy, evidence‐based recommendations regarding the management of inhaled allergies with immunotherapy. Specific goals of the guideline are to optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce the risk of harm. The target patients for the guideline are any individuals aged 5 years and older with AR, with or without AA, who are either candidates for immunotherapy or treated with immunotherapy for their inhalant allergies. The target audience is all clinicians involved in the administration of immunotherapy. This guideline is intended to focus on evidence‐based quality improvement opportunities judged most important by the guideline development group (GDG). It is not intended to be a comprehensive, general guide regarding the management of inhaled allergies with immunotherapy. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients. Action Statements The GDG made a strong recommendation that (Key Action Statement [KAS] 10) the clinician performing allergy skin testing or administering AIT must be able to diagnose and manage anaphylaxis. The GDG made recommendations for the following KASs: (KAS 1) Clinicians should offer or refer to a clinician who can offer immunotherapy for patients with AR with or without AA if their patients' symptoms are inadequately controlled with medical therapy, allergen avoidance, or both, or have a preference for immunomodulation. (KAS 2A) Clinicians should not initiate AIT for patients who are pregnant, have uncontrolled asthma, or are unable to tolerate injectable epinephrine. (KAS 3) Clinicians should evaluate the patient or refer the patient to a clinician who can evaluate for signs and symptoms of asthma before initiating AIT and for signs and symptoms of uncontrolled asthma before administering subsequent AIT. (KAS 4) Clinicians should educate patients who are immunotherapy candidates regarding the differences between SCIT and SLIT (aqueous and tablet) including risks, benefits, convenience, and costs. (KAS 5) Clinicians should educate patients about the potential benefits of AIT in (1) preventing new allergen sensitizations, (2) reducing the risk of developing AA, and (3) altering the natural history of the disease with continued benefit after discontinuation of therapy. (KAS 6) Clinicians who administer SLIT to patients with seasonal AR should offer pre‐ and co‐seasonal immunotherapy. (KAS 7) Clinicians prescribing AIT should limit treatment to only those clinically relevant allergens that correlate with the patient's history and are confirmed by testing. (KAS 9) Clinicians administering AIT should continue escalation or maintenance dosing when patients have local reactions (LRs) to AIT. (KAS 11) Clinicians should avoid repeat allergy testing as an assessment of the efficacy of ongoing AIT unless there is a change in environmental exposures or a loss of control of symptoms. (KAS 12) For patients who are experiencing symptomatic control from AIT, clinicians should treat for a minimum duration of 3 years, with ongoing treatment duration based on patient response to treatment. The GDG offered the following KASs as options : (KAS 2B) Clinicians may choose not to initiate AIT for patients who use concomitant beta‐blockers, have a history of anaphylaxis, have systemic immunosuppression, or have eosinophilic esophagitis (SLIT only). (KAS 8) Clinicians may treat polysensitized patients with a limited number of allergens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnaphylaxisAsthmaRhinitis, AllergicHumansAllergensDesensitization, Immunologic

Stichwörter der Autor:innen

allergen immunotherapyallergic asthmaallergic rhinitisanaphylaxisinhalant allergysubcutaneous immunotherapysublingual immunotherapy

Substanzen

Allergens

Autor:innen und Institutionen

  • University of Utah, Salt Lake City, Utah, USA.
  • The University of Chicago Medicine, Chicago, Illinois, USA.
  • Lake Mary ENT and Allergy, Lake Mary, Florida, USA.
  • Wake Forest Baptist Health, Winston Salem, North Carolina, USA.
  • University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Anderson ENT & Facial Plastics, Anderson, South Carolina, USA.

ORCID-Profile: Joe Reyes

Förderung

  • Intramural NIH HHS

Zitieren

APA

Gurgel, R. K., Baroody, F. M., Damask, C. C., Mims, J. W., Ishman, S. L., Baker, D. P., Contrera, K. J., Farid, F. S., Fornadley, J. A., Gardner, D. D., Henry, L. R., Kim, J., Levy, J. M., Reger, C. M., Ritz, H. J., Stachler, R. J., Valdez, T. A., Reyes, J., & Dhepyasuwan, N. (2024). Clinical Practice Guideline: Immunotherapy for Inhalant Allergy. Otolaryngology–Head and Neck Surgery, 170(S1). https://doi.org/10.1002/ohn.648

Vancouver

Gurgel RK, Baroody FM, Damask CC, Mims JW, Ishman SL, Baker DP, et al. Clinical Practice Guideline: Immunotherapy for Inhalant Allergy. Otolaryngology–Head and Neck Surgery. 2024;170(S1). doi:10.1002/ohn.648

BibTeX
@article{Gurgel2024,
  author = {Gurgel, Richard K and Baroody, Fuad M and Damask, Cecelia C and Mims, James Whit and Ishman, Stacey L and Baker, Dole P and Contrera, Kevin J and Farid, Fariha S and Fornadley, John A and Gardner, Donna D and Henry, LaKeisha R and Kim, Jean and Levy, Joshua M and Reger, Christine M and Ritz, Howard J and Stachler, Robert J and Valdez, Tulio A and Reyes, Joe and Dhepyasuwan, Nui},
  title = {Clinical Practice Guideline: Immunotherapy for Inhalant Allergy},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  volume = {170},
  number = {S1},
  doi = {10.1002/ohn.648}
}
Kostenlos starten →